INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 12 hours ago

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.

GlobeNewsWire • Oct 26, 2026

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

Business Wire • Oct 18, 2026

Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company's first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME's annual list of the Best Inventions features 300 extraordinary inventions changing lives.

GlobeNewsWire • Oct 15, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

Zacks Investment Research • Oct 14, 2026

Syndax Pharmaceuticals Suffers Pipeline Blow

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial.

Benzinga • Oct 13, 2026

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of investors who lost money.

PRNewsWire • Oct 14, 2026

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 200 points on Tuesday. Shares of Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) fell sharply in pre-market trading after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.

Benzinga • Oct 13, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC). The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new safety signals identified.

GlobeNewsWire • Oct 12, 2026